Data shared in oral presentation at American Diabetes Association 82 nd Scientific Sessions® and published in Kidney360 highlights importance in early understanding of cardiovascular risk, a leading cause of death in patients with diabetes and chronic kidney disease NEW YORK and SALT LAKE CITY,

RNS Number : 6870N Renalytix PLC 06 June 2022   Renalytix plc ("Renalytix" or the "Company")   Renalytix held Two Data Presentations on KidneyIntelX at American Diabetes Association 82 nd Scientific Sessions®   Real-world clinical utility in 1,112 patients tested with   KidneyIntelX KidneyIntelX

RNS Number : 6872N Renalytix PLC 06 June 2022   Renalytix plc ("Renalytix" or the "Company")   KidneyIntelX TM Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort   Data shared in oral presentation at American

Real-world clinical utility in 1,112 patients tested with KidneyIntelX KidneyIntelX stratification for cardiovascular risk in 1,278 diabetic kidney disease patients NEW YORK and SALT LAKE CITY, June 02, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its

RNS Number : 9425J Renalytix PLC 29 April 2022   Renalytix plc   (" Renalytix " or the " Company ")     Total voting rights   NEW YORK and SALT LAKE CITY , 29 April, 2022 - Renalytix (LSE: RENX) announces that t he Company's total issued share capital consists of 74,760,432 shares of 0.25 pence

RNS Number : 9726I Renalytix PLC 22 April 2022     Renalytix plc ("Renalytix" or the "Company")   Grant of Share Options   New York and SALT LAKE CITY , April  22, 2022   -   Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Remuneration Committee has agreed to issue options over a total

Director/PDMR Dealing NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY

NEW YORK and SALT LAKE CITY, April 08, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares") have been issued to

RNS Number : 7218H Renalytix PLC 08 April 2022   Renalytix plc ("Renalytix" or the "Company")   Issue of shares   NEW YORK and SALT LAKE CITY , 8 April, 2022 - Renalytix Plc   (NASDAQ: RNLX) (LSE: RENX)   announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new

RNS Number : 7737H Renalytix PLC 08 April 2022   NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,  CANADA ,  AUSTRALIA , JAPAN , THE REPUBLIC OF SOUTH AFRICA , NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR